To provide an overview of recent clinical trial data on Datopotamab deruxtecan (Dato-DXd) and propose future research directions.
Approach:
Clinical Trials Overview: Summarizes data from multiple clinical trials demonstrating the efficacy and safety profile of Dato-DXd across various solid tumors.
Future Research Directions: Proposes addressing optimal sequencing strategies, overcoming drug resistance, and managing treatment-related adverse events.
Key Findings:
Dato-DXd is a TROP2-targeting ADC that combines a humanized monoclonal antibody with a potent topoisomerase I inhibitor.
It has shown compelling efficacy and a manageable safety profile in clinical trials.
Dato-DXd has been approved for treatment in adult patients with hormone receptor-positive, HER2-negative breast cancer and locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.
Interpretation:
Limitations:
The article does not provide detailed results from specific clinical trials.
Future research directions are proposed but not yet validated.
